Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
8 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT05587296 | A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer(OASIS-4) | active not recruiting | Phase 3 | 474 | BayerINDUSTRY |
| 16 |
| Jul 9, 2026 |
| clinicaltrials |
| NCT06509880 | Immunosurveillance for Metastatic Colorectal Cancer(ISMCC) | completed | Phase 2 / Phase 3 | 187 | MIPO ClinicOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT03191786 | A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy(IPSOS) | completed | Phase 3 | 453 | Hoffmann-La RocheINDUSTRY | 24 | Oct 23, 2024 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT01254279 | Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen | completed | Phase 3 | 984 | SanofiINDUSTRY | 29 | Jan 21, 2015 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials